Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Operating Leases for 3 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 25.42% to $7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.9 million, a 25.42% decrease, with the full-year FY2025 number at $7.9 million, down 25.42% from a year prior.
  • Operating Leases was $7.9 million for Q4 2025 at Artiva Biotherapeutics, down from $8.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $15.5 million in Q2 2024 to a low of $7.9 million in Q4 2025.
  • A 3-year average of $10.9 million and a median of $10.4 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: fell 20.62% in 2024, then tumbled 38.35% in 2025.
  • Artiva Biotherapeutics' Operating Leases stood at $13.3 million in 2023, then dropped by 20.62% to $10.6 million in 2024, then fell by 25.42% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Operating Leases are $7.9 million (Q4 2025), $8.5 million (Q3 2025), and $9.6 million (Q2 2025).